- Stockwatch: Oscillating fortunes
- AAIC: Lilly's solanezumab delays Alzheimer's progression by 34%
- Lilly sets timelines for solanezumab
- Stockwatch: Drug reimbursement Elysium?
- INTERVIEW: Clinuvel's Philippe Wolgen on Scenesse and the patient factor
- Profile: Janssen R&D boss on the next big thing in medicine & 'ice bucket' funding